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Abstract
Increasing resistance due to the production of ESBL in Escherichia coli (ESBL-E. coli) has become a major threat to public health.
Our aims were to study the incidence of ESBL-E. coli acquisition during hospitalization and the transmission rates of different ESBL-
E. coli clones. This was a prospective case–control study, conducted in two geriatric rehabilitation wards in Tel-Aviv. Serial rectal
cultures were collected from admission till discharge. All patient-unique ESBL-E. coli isolates were subjected to molecular typing by
PFGE, MLST and determination of ESBL genes. An acquisition of ESBL-E. coli was defined as traceable when a patient with the same
ST, PFGE type and ESBL gene was hospitalized in the same ward in parallel to the acquisition case. ESBL-E. colis were recovered
from 125 patients out of 492 enrolled: 52 were recovered upon admission, 59 acquired ESBL-E. coli during their stay, and there
was undetermined status in 14 patients. A low Norton’s score was associated with acquisition (O.R. 1.14 for each point, 95% C.I.
1.01–1.29, p < 0.05). ESBL-E. coli infections (n = 9) had occurred only in ESBL-E. coli carriers. The pandemic ST131 clone was the
most common (48/125). The majority of the isolates (101/125) produced CTX-M-type ESBL. Of the 59 acquisition cases, 32 were
traced to another patient. In-hospital dissemination was highest in the CTX-M-27-producing ST131 and the SHV-5-producing ST372
sub-clones (acquisition/admission ratios of 17/11 and 9/3, respectively), with almost all cases traced to other patients. In conclusion,
most ESBL-E. coli acquisition cases were traceable to other patients. The transmission potential varied significantly between ESBL-
E. coli clones.
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Introduction
Escherichia coli is the most common aetiological agent of uri-
nary tract infection in humans of all age groups. In addition,
it is a frequent cause of other types of infections, ranging
from intra-abdominal infections to neonatal meningitis [1]. In
the last three decades, we have witnessed increasing resis-
tance due to the production of extended-spectrum b-lactam-
ase (ESBL) in E. coli (ESBL- E. coli), in both the community
and healthcare settings [2]. Several clones have been identi-
fied recently as leading causes of ESBL- E. coli infections glob-
ally, most notably the uropathogenic sequence type 131
(ST131), belonging to the phylogroup B2 [2]. Mechanisms of
transmission and spread of ESBL- E. coli in healthcare settings
are not fully understood, especially outside the boundaries of
a defined outbreak. Although person-to-person transmission
has been commonly perceived as the most likely mode, this
opinion was not supported in studies that sought to
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correlate ESBL- E. coli acquisition cases with previously
known carriers [3,4]. However, these studies were
conducted in intensive care units (ICUs) [3–5] where direct
patient-to-patient contacts are uncommon; therefore, indi-
rect transmission via healthcare providers or equipment may
play a more important role.
In the present study, we examined the transmission dynam-
ics of ESBL- E. coli in two rehabilitation wards (RWs) in a hos-
pital in Tel-Aviv (Israel). RWs constitute an excellent and so
far non-exploited model for such analyses. Patients admitted
to RWs are commonly hospitalized for longer periods, and
are more ambulant and interactive. Therefore, the potential
for direct transmission between patients may be remarkable,
as well as the opportunity to track it. Our objectives were to
study (i) the prevalence of ESBL- E. coli on admission and the
incidence of its acquisition during hospitalization; (ii) different
risk factors for ESBL- E. coli acquisition; (iii) the transmission
rate of different ESBL- E. coli clones identified by molecular
typing; and (iv) the role of patient-to-patient transmission in
the acquisition of ESBL- E. coli.
Methods
Settings
This study was a part of the project MOSAR (Mastering
Hospital Antimicrobial Resistance and its Spread into the
Community), a trans-disciplinary network funded by the
European Commission, and devoted to combating and con-
trolling resistance in bacteria. The project is focused on
endemic and epidemic nosocomial pathogens in high-risk
medical units, including ICUs, RWs and surgery wards in dif-
ferent European countries and Israel.
The study was conducted in two geriatric RWs (50 beds
combined) at the Tel-Aviv Sourasky Medical Center
(TASMC), and included elderly patients (>65 years of age)
who were admitted to the wards between October 2008
and May 2009 because of orthopaedic or neurological disor-
ders. The patients are mostly admitted requiring heavy assis-
tance in daily activities. Some are incontinent and most are
wheelchair bound. As they improve, they are able to be par-
tially independent, and towards discharge some will be inde-
pendent or almost independent and the rest will still need
moderate help. Most of the patients will be ambulated on
discharge but some will need close observation while walk-
ing. During rehabilitation, the patients stay in a two-bed
room. Patients spend most of the day in a common room,
where they conduct various activities including occupational
and recreational therapy, socialize with each other and dine.
The patients are transferred also to specialized areas such as
physical therapy and the pool. The study was approved by
the ethics committee of the TASMC.
Design and data collection
This was a prospective study, aimed at examining risk factors
for ESBL- E. coli carriage among RW patients. The study had
two parts: (i) a case–control study, where ESBL- E. coli carri-
ers on admission were compared with a control group,
which included patients without ESBL- E. coli on admission;
(ii) a cohort study, where patients not carrying ESBL-Ent on
admission were followed for the acquisition of ESBL- E. coli
(see ‘definition’). Surveillance rectal cultures were collected
from all patients at admission, 2 weeks later, then once
monthly, and at discharge. According to the local infection
control policy, contact isolation was not carried out for
ESBL- E. coli carriers. The following data were recorded:
demographic (patient’s age and sex), medical history including
underlying conditions and co-morbidities, prior hospital or
long-term care facility (LTCF) stay and its duration, Norton
score [6], antibiotic treatment during the last month prior to
admission, the presence of medical devices, history of sur-
gery or other invasive procedures, the incidence of infection
due to ESBL- E. coli, and the discharge destination. Molecular
typing and identification of ESBL genes were performed on
all patient-unique isolates as described below.
Detection of ESBL-EC isolates and their phenotypic charac-
terization
Rectal swabs were streaked onto Brilliance ESBL Agar (Ox-
oid, Basingstoke, UK). Putative ESBL-producing Enterobacteri-
aceae (ESBL-Ent) colonies were identified according to the
manufacturer’s instructions. Pure cultures were frozen at
)80C and shipped to the MOSAR ESBL central laboratory
(National Medicines Institute in Warsaw, Poland) for definite
identification and further analysis. Species identification was
carried out using the Vitek 2 system (bioMe´rieux, Marcy l’Eto-
ile, France). ESBL production was verified using the double-
disk synergy test with disks containing cefotaxime, ceftazidime,
cefepime and amoxicillin with clavulanate on Mueller–Hinton
agar plates (Oxoid) that were not supplemented and supple-
mented with 250 mg/L cloxacillin as previously described [7].
Molecular typing of ESBL-EC isolates
Pulsed-field gel electrophoresis (PFGE) was performed
according to Struelens et al. [8]. PFGE types and subtypes
were discerned by visual analysis using the criteria of Tenov-
er et al. [9]. In order to verify the results, electrophoretic
patterns were compared also with the BioNumerics Finger-
printing software (Version 6.01, Applied Maths, Sint-Martens-
Latem, Belgium), using the Dice coefficient and clustering by
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UPGMA (unweighted pair group method with arithmetic
mean) with 1% tolerance in band position differences. Repre-
sentative E. coli isolates of all PFGE types were subjected to
multilocus sequence typing (MLST) as described previously
[10]. A database available at http://mlst.ucc.ie was used for
assigning sequence types (STs) and clonal complexes.
Identification of ESBLs
ESBL- E. coli isolates were subjected to b-lactamase profiling
by isoelectric focusing as described previously [11] by using a
Model 111 Mini IEF Cell (Bio-Rad, Hercules, CA, USA). Iden-
tification of the ESBL blaCTX-M-1-, blaCTX-M-2-, blaCTX-M-9-,
blaCTX-M-25- and blaSHV-like genes was carried out by PCR as
previously described [12]. Sequencing of the genes was per-
formed for representative isolates as reported [12,13], using
sets of consecutive primers specific for each gene type.
Definitions and data analysis
ESBL- E. coli carriers were divided into ‘admission’ and
‘acquisition’ groups, according to the ESBL- E. coli identifica-
tion time: before and after 72 h from admission, respectively.
In cases when the first rectal culture was collected more
than 72 h from admission, the acquisition status was not
determined. An acquisition of ESBL- E. coli was defined as
traceable when a patient with E. coli of the same ST, PFGE
type and ESBL gene was hospitalized in the same ward in
parallel to the acquisition case; in these cases, patient-to-
patient transmission was assumed.
Risk factors were analysed by comparing the ESBL- E. coli
carriers of the admission and acquisition groups with an ESBL-
Ent-negative group. The control group was selected randomly
from the overall ESBL-Ent-negative patients, using random
study numbers. Equivalent numbers of control and case
patients were selected. Data were analysed using univariate
analysis: continuous variables were compared between the
groups using an unpaired t-test within each group. Categorical
parameters were compared by using the Pearson v2 test.
p-values of £0.05 were considered as a significant difference
between the groups. Multivariate analysis using binary logistic
regression prediction models was constructed using forward
stepwise selection. All data were analysed using the SPSS soft-
ware package version 15.0 (SPSS, Chicago, IL, USA).
Results
Demographic and clinical characteristics of ESBL- E. coli
carriers at TASMC
During the study period, 492 patients were enrolled in the
two RWs; ESBL- E. coli isolates were recovered from 125
patients. Fifty-two patients were colonized upon admission
(admission group), 59 patients acquired ESBL- E. coli during
their stay (acquisition group), and the carriage origin status
was undetermined in 14 patients. Of the 367 ESBL-Ent
patients, 52 were randomly selected as controls. The demo-
graphic and clinical characteristics according to the ESBL-
E. coli carriage status are presented in Table 1. The mean
(range) age was 83 years (65–105), 62 were male (35%) and
the mean (range) length of stay prior to admission was
14 days (1–119). Longer length of stay at an acute-care facil-
ity prior to rehabilitation, incontinence, low Norton score
and cardiovascular disease (CVD) were more common in
the acquisition group when compared with the negative
group. In the multivariate analysis, a low Norton score
remained a significant risk factor for the ESBL- E. coli acquisi-
tion (OR, 1.14 for each point; 95% CI, 1.01–1.29; p < 0.05).
No significant differences were found between the groups in
the overall use of antimicrobial therapy in the preceding
month and in the use of penicillins, b-lactamase+b-lactamase
inhibitors, cephalosporins, carbapenems, quinolones, macro-
lides and aminoglycosides. Transfer to an LCTF or acute-care
facility was significantly more frequent in both the admission
and acquisition groups when compared with the negative
group. Two patients in the admission group passed away.
Infections caused by ESBL- E. coli, including three blood-
stream infections, occurred in nine patients; four patients
were in the acquisition and admission groups each, and one
was in the group with the undetermined carriage status. No
ESBL- E. coli infections occurred among all the 367 ESBL-
E. coli -negative patients hospitalized in the RWs during the
study. In addition, we compared the molecular characteristics
of the E. coli strains (STs and ESBL types) between the
groups according to their defined carriage status. We found
that the rate of strains producing SHV-type ESBLs (SHV-5, -
12) was significantly higher in the acquisition than in the
admission group: 16/59 vs. 6/52 (p < 0.05).
Molecular characteristics of ESBL- E. coli
The results of the molecular analysis of the 125 ESBL- E. coli
isolates are shown in Table 2. The isolates were classified
into 26 STs (clones) and 49 PFGE types. Thirteen clones
were represented by more than one isolate and these were
mainly the clones that have been disseminated globally and/
or belonged to widespread clonal complexes, for example
ST131 (n = 48; 38.5%), ST398 (n = 9; 7%), ST38 (n = 8;
6.5%), ST405 (n = 8; 6.5%), ST69 (n = 6; 5%), ST648 (n = 6;
5%), ST10 (n = 3; 2.5%), ST410 (n = 3; 2.5%) or ST354
(n = 2; 1.5%). The second most prevalent clone was ST372
(n = 13; 10.5%). Most of these clones were differentiated
into several PFGE types; larger clusters belonged to ST131
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(31 isolates of type I), ST372 (12 isolates of type Q), ST398
(all nine isolates of type AS) and ST69 (five isolates of type
B). The majority of the isolates (n = 101; 81%) produced
CTX-M-type ESBLs, namely CTX-M-15 (n = 39; 31%), CTX-
M-27 (n = 32; 25.5%), CTX-M-14 (n = 12; 9.5%), CTX-M-2
(n = 4; 3%), CTX-M-9 (n = 3; 2.5%) and CTX-M-55 (n = 2;
1.5%). The other types were SHV-5 (n = 15; 12%) and SHV-
12 (n = 9; 7%). A single PFGE type usually produced a single
TABLE 1. Demographic and clinical characteristics of patients according to ESBL-producing E. coli (ESBL-E. coli) acquisition
status
Variable









OR (95% CI)b p-value OR (95% CI)b p-value
Male, n (%) 18 (35) 18 (35) 1 (0.44–2.44) NSa 22 (37) 1.12 (0.51–2.44) NS
Mean age, years (95% CI) 81 (79–84) 84 (82–86) 1.04 (0.98–1.09) NS 83 (81–85) 1.02 (0.97–1.08) NS
LTCF stay in last 6 months, n (%) 2 (4) 2 (4) 1 (0.13–7.38) NS 5 (8) 2.31 (0.43–12.47) NS
Mean duration of hospitalization prior to
rehabilitation, days (95% CI)
11 (10–13) 13 (10–16) 1.02 (0.97–1.06) NS 19 (12–25) 1.03 (1–1.07) <0.05
Full continence on admission, n (%) 33 (63) 32 (61) 0.92 (0.41–2.03) NS 25 (43) 0.42 (0.2–0.9) <0.05
Mean Norton scale (95% CI) 14.9 (14–15.9) 14.31 (13.2–15.5) 0.95 (0.85–1.05) NS 13.3 (12.3–14.3) 0.87 (0.77–0.98) <0.05
Active infection on admission, n (%) 4 (8) 4 (8) 1 (0.23–4.23) NS 7 (12) 1.61 (0.44–5.86) NS
Cardiovascular disease
(including hypertension), n (%)
36 (69) 43 (83) 2.12 (0.83–5.37) NS 51 (86) 2.83 (1.09–7.32) <0.05
Congestive heart failure, n (%) 3 (6) 4 (8) 1.36 (0.28–6.4) NS 4 (7) 1.18 (0.25–5.57) NS
History of a stroke, n (%) 9 (17) 10 (19) 1.13 (0.42–3.07) NS 14 (24) 1.48 (0.58–3.78) NS
Chronic lung disease, n (%) 5 (10) 12 (23) 2.23 (0.7–7.07) NS 4 (7) 0.68 (0.17–2.69) NS
Renal impairment, n (%) 9 (17) 10 (19) 1.13 (0.42–3.07) NS 9 (15) 0.86 (0.31–2.36) NS
Diabetes, n (%) 20 (38) 12 (23) 0.48 (0.20–1.12) NS 14 (24) 0.49 (0.21–1.13) NS
History of malignancy, n (%) 8 (15) 8 (15) 1 (0.34–2.9) NS 14 (24) 1.71 (0.65–4.48) NS
Urinary catheter/other invasive device, n (%) 47 (90) 43 (83) 0.5 (0.15–1.63) NS 47 (80) 0.41 (0.13–1.27) NS
Surgery/invasive procedure in last year, n (%) 41 (79) 35 (67) 0.55 (0.22–1.33) NS 39 (66) 0.52 (0.22–1.23) NS
Antibiotic in the past month, n (%) 40 (77) 37 (71) 0.74 (0.3–1.78) NS 49 (83) 1.47 (0.57–3.75) NS
Antibiotic Rx on admission, n (%) 10 (19) 5 (10) 0.44 (0.14–1.41) NS 8 (14) 0.65 (0.23–1.81) NS
Mean duration of hospitalization in
rehabilitation ward, days (95% CI)
29 (24–33) 24 (20–29) 0.67 (0.31–1.47) NS 35 (29–41) 1.15 (0.54–2.45) NS
Transfer to acute care/LTCF, n (%) 1 (2) 7 (14) 8.5 (1–71) <0.05 9 (15) 9.18 (1.12–75) <0.05
LTCF, long-term care facility.
aNS, p-value > 0.05.
bOR and 95% CI for continuous variables are calculated per 1 unit.
TABLE 2. Clonal structure, resis-
tance genes and acquisition status
of ESBL-producing E. coli isolates
at TASMC





131 (48) CTX-M-15 (14) 4 AD-8, AQ-5, ND-1 2
CTX-M-27 (31) 1 AD-11, AQ-17, ND-3 16
CTX-M-14,-39,-55 (3) 2 AD-2, AQ-1 1
372 (13) SHV-5 (12) 1 AD-3, AQ-9 8
CTX-M-15 (1) 1 AQ-1 0
398 (9) CTX-M-39 (8) 1 AD-4, AQ-4 2
SHV-5 (1) 1 AQ-1 0
38 (8) CTX-M-9, -14, -15, -27 7 AD-4, AQ-4 0
405 (8) CTX-M-9, -15; SHV-12 6 AD-2, AQ-3, ND-3 1
69 (6) CTX-M-14 (5) 1 AD-2, AQ-1, ND-2 0
CTX-M-15 (1) 1 AQ-1 0
648 (6) CTX-M-14 (5) 2 AD-2, AQ-2, ND-1 1
CTX-M-15 (1) 1 AD-1 NA
10 (3) CTX-M-14; SHV-5, -12 3 AD-2, AQ-1 0
410 (3) SHV-12 2 AD-1, AQ-2 1
216 (2) SHV-12 2 AQ-1, ND-1 0
354 (2) CTX-M-2,-15 1 AD-1, AQ-1 0
1196 (2) CTX-M-2 1 AD-2 NA
1598 (2) CTX-M-15 1 AD-1, ND-1 NA
Msc (13) CTX-M-2 (1),-14 (2),-15 (6),-55
(1); SHV-5 (1),-12 (2)
13 AD-6, AQ-5, ND-2 0
Total (125) AD-52, AQ-59, ND-14 32
ST, sequence type; PFGE, pulse-field gel electrophoresis types; AD, isolated on admission to rehabilitation ward; AQ,
acquisition at the rehabilitation ward; ND, not determined; NA, not applied.
aPartially presented in Fig. 2.
bAcquisition source traced to another patient.
cMs, miscellaneous ST (one each): 48, 59, 62, 95, 348, 449, 469, 641, 746, 929, 940, 1596, 1597.
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ESBL type (e. g. the ST131 PFGE type I had CTX-M-27 and
the ST372 type Q had SHV-5). Only 14 ST131 isolates pro-
duced CTX-M-15, and these belonged to four PFGE types.
Clonal transmission of ESBL- E. coli strains at TASMC
The carriage status of each patient was analysed against the
clonality (ST) and ESBL data (Table 2). The overall acquisition
to admission ratio was 1.1 (59/52). Of the major ST and ESBL
combinations (>5 isolates each), the highest ratio of 3.0 was
observed for the SHV-5-producing ST372 sub-clone (9/3,
p = 0.06), while it was 1.5 (17/11) for the CTX-M-27-producing
ST131, 1.0 (4/4) for the CTX-M-39-producing ST398, and 0.62
(5/8) for the CTX-M-15-producing ST131. In order to under-
stand the transmission dynamics of the various ESBL- E. coli
clones, we compared in parallel the hospitalization periods of
the patients carrying the same ST, PFGE and ESBL types
(Table 2). The results obtained for the main sub-clones are pre-
sented in Figs 1 and S1. Overall, the transmission could be
traced in 32 out of the 59 acquisition cases (54%). The rate of
traceable cases was significantly higher for the SHV-5-producing
ST372 (8/9, p < 0.05) and the CTX-M-27-producing ST131 sub-
clones (16/17, p < 0.001) than for the remaining subclones.
Discussion
In the present study, we analysed the incidence and transmis-
sion of ESBL- E. coli clones in a rehabilitation centre. We
have analysed all cases of colonization with ESBL- E. coli,
which allowed us to assess the factual complexity of the epi-
demiological issues and trace the dissemination of ESBL-
E. coli more precisely.
The incidence of ESBL- E. coli acquisition was common (59
out of 426 ESBL- E. coli -negative patients, 14%), exceeding
the number of patients positive at admission (n = 52/492,
10.5%). The rate of ESBL- E. coli carriage on admission was
similar to previous studies in Israel [14,15]. The acquisition
incidence was lower compared with a previous study in an
acute care hospital in Israel [14] but was higher compared
with the incidence reported from France [16]. This might be
explained by the differences in the prevalence of ESBL- E. coli
and the overall quality of infection control practices between
the institutions. In particular, the lack of implementation of
contact precautions might have contributed to the high
acquisition rate. This policy was implemented due to the high
rate of ESBL-Ent carriage upon admission. The high acquisi-
tion rate found in our study may serve as a warning and
guide other institutions that do not have such a high baseline
carriage rate to implement contact isolation of these
patients, even in the set-up of LCTF. Despite similar clinical
characteristics upon admission, ESBL- E. coli carriers had a
worse outcome in terms of discharge destination (higher
rate of transfer to another healthcare facility vs. home), as
well as developing infections caused by ESBL- E. coli.
This study is also the first large molecular analysis of
ESBL- E. coli in Israel. The pandemic ST131 clone spread
both in hospitals and in the community, was highly predomi-
nant, accounting for 38.5% of the isolates, similar to other
countries [2]. Other globally spread E. coli clones, including
ST10, ST38, ST69, ST354, ST398, ST405, ST410 and ST648
[17–23], were observed as well; together with ST131 all
these clones comprised around 74.5% of the isolates (93/
125). Of the relatively less common clones, the SHV-5-pro-
ducing ST372 [22] was remarkably prevalent, and had the
highest acquisition to admission ratio (3.0) when compared
with the overall value (1.1). Therefore, it contributed to the
role of SHV-producing ESBL- E. coli as a significant factor
associated with acquisition, which is congruent with the gen-
eral view of SHV producers being associated more with hos-
pital environments than the community [24,25]. Surprisingly,
of the ST131 sub-clones, the one with CTX-M-27 had a
higher acquisition to admission ratio (1.5), than those pro-
ducing CTX-M-15 (0.62), the enzyme so often found in
ST131 [2]. There are several possible explanations for this
finding. First, incidental events might have led to an outbreak
of the CTX-M-27-producing ST131 sub-clone. Second, while
CTX-M-15-producing ST131 spread readily in hospitals but
also in the community [2], the CTX-M-27-producing sub-
clone may fit better to in-hospital spread. Third, as most
molecular epidemiology studies, unlike the current work,
focused mainly on clinical rather than surveillance-culture
isolates [2], the relative rate of colonization to infection of
the particular clones may be different. Fourth, it is possible
that the CTX-M-27-producing ST131sub-clone (as is the
SHV-5-producing ST372 sub-clone) is currently emerging and
may become more important in Israel in the coming years.
Of note, the CTX-M-27-producing ST131 sub-clone was
remarkably homogeneous (corresponding to a single pre-
dominant PFGE type among all seven ST131 types). In con-
trast, CTX-M-15 was produced by ST131 isolates that were
classified into four PFGE types. All these findings should be
analysed with caution as this study was limited to a single
facility, and unidentified differences between the individual
patients or particular circumstances may have played a role
in facilitating transmission of particular sub-clones.
In this study, traceable patient-to-patient transmission was
identified in 32/59 cases (54%) and was highest in the SHV-
5-producing ST372 (8/9) and the CTX-M-27-producing
ST131 (16/17) sub-clones. Several studies have investigated
the transmission of different ESBL-Ent clones in ICUs [3–5].
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FIG. 1. Transmission dynamics of ESBL-producing E. coli sub-clones at TASMC. (a) ST131-CTX-M-27, ward A; (b) ST131-CTX-M-27, ward B; (c)
ST131-CTX-M-15, ward B; (d) ST372-SHV-5, ward A. Lines correspond with hospitalization’s timing for each patient. The X on each line marks
the date of first positive culture; the colours on Panel c represent different PFGE types.
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In the study by Harris et al., using similar definitions, the
traceable acquisition rate was only 3/23 (13%) [3], leading to
the conclusion that patient-to-patient transmission does not
play an important role in ESBL-Ent acquisition. Compared
with that analysis, our study had more opportunity to study
the natural course of ESBL- E. coli clonal transmission for
several reasons: first, unlike in ICUs where direct patient-to-
patient contact is minimal, patients in RWs are ambulant and
share many common facilities inside the ward, a condition
that may facilitate direct transmission; second, the number of
ESBL- E. coli carriers identified (125/492) was high enough to
allow the analysis of the transmission potential of different
clones; third, the longer length of patients’ stay in our study
allowed for the serial survey of ESBL- E. coli carriage and
thus better detection of acquisition events.
Several reasons may account for the 27 untraceable cases.
First, ESBL-E. coli might have been transmitted from clini-
cally-infected patients who were not analysed in our study.
However, this is rather unlikely as all ESBL- E. coli infections
occurred in colonized patients. Second, infection might be
transmitted from other sources, such as colonized staff or
food [26]. Indeed, 7% of staff members were found to be
colonized by ESBL- E. coli in two surveys conducted during
the study (data not shown). Third, previously colonized
patients may have been misclassified as new acquisitions due
to false-negative results of the admission culture. And last, it
is possible that transmission of ESBL genes via mobile genetic
elements [23,27] might account for some of the acquisition
cases. In order to explore this hypothetical possibility, we
analysed the patient-to-patient transmission in the 25 clon-
ally-diverse (n = 16), blaCTX-M-15-carrying ESBL- E. coli iso-
lates in ward B (Fig. 2). We were able to trace only two of
the nine acquisition cases by clonal transmission, whereas
the mobile genetic element transmission hypothesis would
allow us to trace all the seven additional cases. Also, it is
possible that such transfer might occur from non-E. coli
species. Further analyses of plasmids and the genetic
environment surrounding the ESBL genes are required in
order to examine this hypothesis.
An important limitation of our study relates to the tracing
of the sources of ESBL-E. coli acquisition, which was limited
to other patients only. However, other sources such as staff
members or the environment might have contributed to the
transmission in some of the acquisition cases and therefore
individual patient-to-patient transmission cannot be proven
with certainty.
This study highlights the importance of patient-to-patient
transmission in the acquisition of ESBL- E. coli during hospi-
talization in rehabilitation centres and the varying dissemina-
tion potential of different clones. Consequently, we believe
that infection control practices should be adapted and imple-
mented in these institutions. Further studies are required to
explore the dynamics of other Enterobacteriaceae species in
other healthcare settings.
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